Artificial Intelligence in Medicine
Volume 41, Issue 3 , Pages 223-235 , November 2007

On macroeconomic characteristics of pharmaceutical generics and the potential for manufacturing and consumption under fuzzy conditions

  • Fernando Gascón

      Affiliations

    • Faculty of Economics, Business Administration and Accounting Department, University of Oviedo, Campus Cristo s/n, 33006 Oviedo, Spain
    • ,
  • David de la Fuente

      Affiliations

    • Polytechnic School of Engineering-Gijón, Business Administration and Accounting Department, University of Oviedo, Campus Viesques s/n, 33204 Gijón, Asturias, Spain
    • ,
  • Javier Puente

      Affiliations

    • Polytechnic School of Engineering-Gijón, Business Administration and Accounting Department, University of Oviedo, Campus Viesques s/n, 33204 Gijón, Asturias, Spain
    • Corresponding Author InformationCorresponding author at: Escuela Politécnica Superior de Ingeniería de Gijón, Universidad de Oviedo, Campus Viesques s/n, 33204 Gijón, Asturias, Spain. Tel.: +34 985181996; fax: +34 985182010.
    • ,
  • Jesús Lozano

      Affiliations

    • Polytechnic School of Engineering-Gijón, Business Administration and Accounting Department, University of Oviedo, Campus Viesques s/n, 33204 Gijón, Asturias, Spain

Received 30 October 2006 ,Revised 15 June 2007 ,Accepted 6 July 2007.

References 

  1. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89–103
  2. Petrova GI. Monitoring of national drug policies—regional comparison between Bulgaria, Romania, Macedonia, Bosnia Herzegovina. Cent Eur J Public Health. 2001;9(4):205–213
  3. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy. 2000;51(3):149–162
  4. Garattini S. The drug market in four European countries. Pharmacoeconomics. 1998;14(Suppl. 1):69–79
  5. Garattini L, Salvioni F, Scopelliti D, Garattini S. A comparative analysis of the pharmaceutical market in four European countries. Pharmacoeconomics. 1994;6(5):417–423
  6. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002;43(4):462–469
  7. Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 2000;54(2):87–123
  8. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plan Manage. 2005;20(4):291–306
  9. Wiktorowicz ME. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France. J Health Polit Policy Law. 2003;28(4):615–658
  10. Kondro W. Canada to change patent law to allow export of cheap drugs. Lancet. 2003;362(9392):1290
  11. Kanavos P, Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics. 1999;15(6):519–533
  12. Dickson M, Redwood H. Pharmaceutical reference prices. How do they work in practice?. Pharmacoeconomics. 1998;14(5):471–479
  13. Rovira J. Are national drug expenditure control policies compatible with a single European market?. Pharmacoeconomics. 1996;10(Suppl. 2):4–13
  14. Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur J Health Econ. 2004;5(2):175–182
  15. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy. 2004;68(1):47–54
  16. McGettigan P, McManus J, O'Shea B, Chan R, Feely J. Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers’ concerns. Irish Med J. 1997;90(4):146–147
  17. Parkin M, Bade R. Modern macroeconomics. 2nd ed.. London: Philip Allan; 1988;
  18. Replogle J. Central American trade pact may limit access to generics. Critics say agreement puts profits ahead of public health. Lancet. 2004;363(9421):1612–1613
  19. Ortún V. Patentes, regulación de precios e innovación en la industria farmacéutica. Cuadernos Económicos de ICE 2004;67:191–207.
  20. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. OECD Labour Market and Social Policy Occasional Papers. 2000. p.40.
  21. El Feki S. The next big thing. India and China hold great pharmaceutical promise. The Economist – Survey: Pharmaceuticals. June 16th, 2005.
  22. Vekeman G. The pharmaceutical industry in the European Union. In: Industry, trade and services—statistics in focus. Eurostat Publications; 2005. p. 44. http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-NP-05-044/EN/KS-NP-05-044-EN.PDF. (Accessed: 20 May, 2007).
  23. Web of the Association of Bulgarian Pharmaceutical Manufacturers http://www.abphm.bg. (Accessed: 25 May, 2007).
  24. Kanavos P. Costa-Font, J Pharmaceutical parallel trade in Europe: stakeholder and competition effects. Economic Policy, CEPR, CES, MSH 2005;20(44):751–98.
  25. Zadeh LA. Fuzzy sets. Inform Control. 1965;8:338–353
  26. Lootsma F. Fuzzy logic for planning and decision-making. Dordrecht: Kluwer; 1997;
  27. Driankov D, Hellendoorn H, Reinfrank M. An introduction to fuzzy control. 2nd ed. Berlin: Springer-Verlag; 1996;
  28. Chen CB, Klein CM. An efficient approach to solving fuzzy MADM problems. Fuzzy Sets Syst. 1997;88:51–67
  29. Lee CC. Fuzzy logic in control systems: fuzzy logic controller. Part I and Part II. IEEE Trans Syst Man Cybern. 1990;20(2):404–435
  30. Lin C, Lee CSG. Neural fuzzy systems. Englewood Cliffs, NJ: Prentice-Hall; 1996;
  31. Rudin W. Principles of mathematical analysis. New York: McGraw Hill; 1976;
  32. Ross TJ. Fuzzy logic with engineering applications. London: Prentice-Hall; 1995;
  33. Mamdani EH, Gains BR. Fuzzy reasoning and its applications. New York: Academic Press; 1981;
  34. El Feki S. The cost of living. Drug prices need fresh thought. The Economist – Survey: Pharmaceuticals. June 16th, 2005.
  35. Anell A. Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy. 2005;75(1):9–17
  36. The World's top ten generic companies 2005. Visiongain Reports. http://www.leaddiscovery.co.uk/target-discovery/PharmaReports.html. (Accessed: 20 May, 2007).

PII: S0933-3657(07)00084-X

doi: 10.1016/j.artmed.2007.07.001

Artificial Intelligence in Medicine
Volume 41, Issue 3 , Pages 223-235 , November 2007

Article Tools

* Image Usage & Resolution